fig2
From: The arsenic trioxide paradox: a targeted therapy triumph in APL versus a metabolic bottleneck beyond
Figure 2. Mechanism of arsenic trioxide (ATO) in acute promyelocytic leukemia (APL) vs. multi-faceted barriers in non-APL cancers.
